Vincerx Pharma (NASDAQ:VINC – Get Free Report) is anticipated to release its resultson Friday, March 27th. Analysts expect Vincerx Pharma to post earnings of ($2.20) per share for the quarter.
Vincerx Pharma Stock Performance
Vincerx Pharma stock opened at $0.01 on Friday. The firm has a market cap of $66,471.80, a price-to-earnings ratio of 0.00 and a beta of 1.56. Vincerx Pharma has a 1 year low of $0.00 and a 1 year high of $0.69. The firm’s 50 day moving average price is $0.01 and its two-hundred day moving average price is $0.02.
Vincerx Pharma Company Profile
Vincerx Pharma, Inc, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with hematologic malignancies and other oncology indications. The company’s research platform centers on selective kinase inhibition and biomarker-driven approaches, with the goal of addressing high unmet medical needs in blood cancers that have limited treatment options.
Vincerx’s lead product candidate, pacritinib—an oral JAK2/IRAK1 inhibitor—was in-licensed from CTI BioPharma Corp.
Further Reading
Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
